Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy…

Principal Investigator: Iyer, Renuka V

NRG-GY025: A RANDOMIZED PHASE II TRIAL OF NIVOLUMAB AND IPILIMUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN PATIENTS WITH DEFICIENT MISMATCH REPAIR SYSTEM RECURRENT ENDOMETRIAL CARCINOMA

Principal Investigator: Zsiros, Emese

A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

Principal Investigator: Gandhi, Shipra

(ACCL2031) A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Principal Investigator: Twist, Clare J

(MCC 21704) A Multi-Institution Study of TGFb; imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue…

Principal Investigator: Gupta, Ajay

A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma

Principal Investigator: Gupta, Ajay

Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with…

Principal Investigator: Wang, Eunice S

NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant
Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy
in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer
and an Oncotype Recurrence…

Principal Investigator: Levine, Ellis G

A bilingual virtually-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors

Principal Investigator: Kelly, Kara M

A Phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy for advanced non-small cell lung cancer

Principal Investigator: Jain, Prantesh

Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant

Principal Investigator: Ross, Maureen

A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Principal Investigator: Wang, Eunice S

AB-1015-101: AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-1015 IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER

Principal Investigator: Zsiros, Emese

An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T…

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

GI-200: A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in
Advanced Refractory Gastric Cancer Patients

Principal Investigator: Mukherjee, Sarbajit

(S1931) Phase III Trial of Immunotherapy-Based Drug Combination Therapy With Or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE TRIAL)

Principal Investigator: George, Saby

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors

Principal Investigator: Puzanov, Igor

Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients with Respiratory Viral Infections After Hematopoietic Cell or Solid Organ Transplant (P…

Principal Investigator: Ross, Maureen

A Phase 0 Study of EGF-depleting therapy CIMAvax-EGF in Combination with Standard Therapy for RAS- and BRAF wild-type Metastatic Colorectal Cancer

Principal Investigator: Vadehra, Deepak

Protocol EAY191-E4, ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors

Principal Investigator: Levine, Ellis G

A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

Principal Investigator: Frederick, Peter

(ACNS2031) A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features

Principal Investigator: Twist, Clare J

A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer

Principal Investigator: Zsiros, Emese

2215-CL-0203 A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for…

Principal Investigator: Wang, Eunice S

Phase 2 study of iberdomide maintenance therapy following autologous stem cell transplant in patients with multiple myeloma

Principal Investigator: Hillengass, Jens